Nktx stock forecast.

View the latest Nkarta Inc. (NKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comStock Price Forecast. The 13 analysts offering 12-month price forecasts for Macy's Inc have a median target of 15.00, with a high estimate of 19.00 and a low estimate of 11.00. The median estimate ...NKTX : Nkarta stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical Analysis

Jun 2, 2023 · Analyst Price Forecast Suggests 852.85% Upside As of June 2, 2023, the average one-year price target for Nkarta is 26.78. The forecasts range from a low of 18.18 to a high of $33.60.

Nkarta Stock Forecast, "NKTX" Share Price Prediction Charts Is "Nkarta Inc" a Good Investment? Current price today: 2.675 USD (+0.753%) History Forecast Data Market …

6.1%. 10% most volatile stocks in US Market. 15.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: NKTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 35% a week. Volatility Over Time: NKTX's weekly volatility has increased from 20% to 35% over the past year.Nkarta Inc. analyst ratings, historical stock prices, earnings estimates & actuals. NKTX updated stock price target summary.Complete Nkarta Inc. stock information by Barron's. View real-time NKTX stock price and news, along with industry-best analysis.Find real-time NXPI - NXP Semiconductors NV stock quotes, company profile, news and forecasts from CNN Business.Nkarta Inc [NKTX] stock prices are up 6.02% to $2.64 at the moment. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling. The NKTX shares have gain 1.93% over the last week, with a monthly amount glided 30.05%, and seem to be holding

Nkarta (NKTX) is a clinical-stage biopharmaceutical company that develops and commercializes cell therapies for cancer treatment. The company's co-lead product candidates are NKX101 and NKX019, which are in phase I trials for various B cell malignancies. Analysts have a consensus rating of Buy and a price target of $15.67, up 671.8% from its current price of $2.03.

It has underperformed other stocks in the Biotechnology industry by 0.45 percentage points. Nkarta stock is currently +97.66% from its 52-week low of $1.28, and -72.62% from its 52-week high of $9.24. As of Nov 20, 2023, there are 49.07M shares of NKTX outstanding. The market cap of NKTX is $124.15M. In the past 24 hours, 524,249 NKTX shares ...

Nkarta, Inc. (NKTX) share price prediction for 2023, 2024, 2025, 2026 and 2027. NKTX one year forecast. Nkarta stock monthly and weekly forecasts. Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...Oct 11, 2023 · An investor can expect a potential return of 1007.01% based on the average NKTX price forecast. Analyzing the NKTX fundamentals To continue investigating profitability, this company’s Return on Assets is posted at -30.48, Equity is -36.53, Total Capital is -33.11, and Invested Capital is -31.98. Based on 10 Wall Street analysts offering 12 month price targets for Livent in the last 3 months. The average price target is $25.30 with a high forecast of $35.00 and a low forecast of $19.00. The average price target represents a 84.00% change from the last price of $13.75. Highest Price Target $35.00. Average Price Target $25.30.Nkarta (NASDAQ:NKTX) is a biopharmaceutical company that develops engineered natural killer (NK) cell therapies to treat cancer.NK cells are a type of immune cell that can recognize and kill tumor ...

Get the latest Nkarta, Inc. (NKTX) stock news and headlines to help you in your trading and investing decisions.The latest price target for . Nkarta (NASDAQ: NKTX) was reported by Mizuho on November 16, 2023.The analyst firm set a price target for $9.00 expecting NKTX to rise to within 12 months (a possible ...May-25-21 07:30AM. Nkarta Announces June 2021 Investor Conference Schedule. (GlobeNewswire) -6.32%. Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials ...Nov 10, 2023 · Nkarta (NKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Maughan from Canaccord Genuity remains neutral on the stock and ... Find the latest Tritium DCFC Limited (DCFC) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...

Be the first to know when Wall Street analysts revise their GSK stock forecasts and price targets. ... 3 Wall Street analysts forecast GSK's revenue for 2024 to be ...In December 2022, Nkarta had US$352m in cash, and was debt-free. Looking at the last year, the company burnt through US$104m. So it had a cash runway of about 3.4 years from December 2022. There's ...

The average Io Biotech stock price prediction forecasts a potential upside of 693.62% from the current IOBT share price of $1.05. What is IOBT's forecast return on ...(See NKTX stock forecast) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stock Screener. Disclaimer: The opinions expressed in this article are ...Mar 20, 2023 · SVB Securities analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) today.The company’s shares opened today at $3.76. According to TipRanks, Graybosch is an ... Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business.Analyst Price Forecast Suggests 852.85% Upside. As of June 2, 2023, the average one-year price target for Nkarta is 26.78. The forecasts range from a low of 18.18 to a high of $33.60. The average ...Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...Find the latest WISeKey International Holding AG (WKEY) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short ...Complete Nkarta Inc. stock information by Barron's. View real-time NKTX stock price and news, along with industry-best analysis.NKTX | Oversold Healthcare Play | LONG Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p Nkarta, Inc., a a clinical-stage biopharmaceutical ...

Nov 28, 2023 · It has underperformed other stocks in the Biotechnology industry by 0.45 percentage points. Nkarta stock is currently +97.66% from its 52-week low of $1.28, and -72.62% from its 52-week high of $9.24. As of Nov 20, 2023, there are 49.07M shares of NKTX outstanding. The market cap of NKTX is $124.15M. In the past 24 hours, 524,249 NKTX shares ...

2 brokers have issued twelve-month target prices for Nutex Health's stock. Their NUTX share price targets range from $1.50 to $3.00. On average, they expect the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 927.4% from the stock's current price.

The average price target for Macy's is $14.83. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $19.00 ,the lowest forecast is $10.00. The average price target represents -0.07% Decrease from the current price of $14.84.This transaction had a minor impact of -0.01% on the firm's portfolio, with the shares being traded at a price of $2.03. Post-trade, T. Rowe Price Investment Management, Inc. (Trades, Portfolio ...A high-level overview of Nkarta, Inc. (NKTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Jun 27, 2023 · On June 22, six executives sold a total of 4,033 shares of Nkarta, including CEO Paul Hastings, who sold 1,704. While company insiders often sell stock for various reasons, the timing of the sales ... Oct. 18, 2023, 08:00 AM Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: In the last 3 months, 7 analysts have offered 12 …Price Performance Review of NKTX. On Tuesday, Nkarta Inc [NASDAQ:NKTX] saw its stock fall -3.25% to $2.53. On the same session, the stock had its day’s lowest price of $2.45, but rose to a high of $2.65. Over the last five days, the stock has gained 10.00%. Nkarta Inc shares have fallen nearly -57.76% since the year began.On March 17, the company reported an earnings loss of 69 cents per share, which did beat the Thomson Reuters forecast of a loss of 75 cents. Research analysts expect Nkarta will post a loss of $3. ...Price Performance Review of NKTX. On Tuesday, Nkarta Inc [NASDAQ:NKTX] saw its stock fall -3.25% to $2.53. On the same session, the stock had its day’s lowest price of $2.45, but rose to a high of $2.65. Over the last five days, the stock has gained 10.00%. Nkarta Inc shares have fallen nearly -57.76% since the year began.Oct. 18, 2023, 08:00 AM Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: In the last 3 months, 7 analysts have offered 12 …Acumen Pharmaceuticals Inc. 2.37. +0.01. +0.42%. Get Nkarta Inc (NKTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Be the first to know when Wall Street analysts revise their GSK stock forecasts and price targets. ... 3 Wall Street analysts forecast GSK's revenue for 2024 to be ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Seven Arts Entertainment share forecasts, stock quote and buy / sell signals below. According to present data Seven Arts Entertainment's SAPX shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Dec 2, 2023 · The consensus price target of analysts on Wall Street is $14.13, which implies an increase of 80.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $25.00 respectively. As a result, NKTX is trading at a discount of -819.12% off the target high and -230.88% off the low. Instagram:https://instagram. stock swingbarron's lumberxpeng didibest individual stocks to buy At the end of Q3 2023, NKTX held $281.2 million in total current assets, $38.2 million of which was held in cash and equivalents, with another $237.4 in short-term investments.Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: In the last 3 months, 7 analysts have offered 12-month price targets for Nkarta. The company has an ... best forex spreadspostpaid atandt Nkarta Inc (NKTX) Company Description. Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable.Find the latest dividend history for Nkarta, Inc. Common Stock (NKTX) at Nasdaq.com. southern company stock dividend What Caused Applied Therapeutics (APLT) Stock to Rise 23% Pre-Market? After announcing a substantial agreement, Applied Therapeutics Inc. (NASD: APLT) has increased 23.01% to $0.9253 in pre-market trading …According to the issued ratings of 2 analysts in the last year, the consensus rating for PMV Pharmaceuticals stock is Buy based on the current 2 buy ratings for PMVP. The average twelve-month price prediction for PMV Pharmaceuticals is $10.00 with a high price target of $15.00 and a low price target of $5.00. Learn more on PMVP's analyst …At the forefront of its drug development, the company is advancing clinical studies of lead cancer vaccine candidate, IO102-IO103, currently being assessed in several programs. The most recent update caused a bit of a stir. Shares tanked by 25% in a single session yesterday after IO said it has now randomized 225 patients into the global Phase ...